Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Acquisitions & Divestments (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Change in Acquisitions & Divestments readings, the most recent being $267.7 million for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 6.74% to $267.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 12.6% increase, with the full-year FY2025 number at $1.1 billion, up 12.6% from a year prior.
  • Change in Acquisitions & Divestments hit $267.7 million in Q4 2025 for Neurocrine Biosciences, up from $225.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $298.6 million in Q2 2025 to a low of $71.2 million in Q3 2022.
  • Median Change in Acquisitions & Divestments over the past 5 years was $204.3 million (2023), compared with a mean of $211.9 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: tumbled 55.42% in 2022 and later surged 283.43% in 2023.
  • Neurocrine Biosciences' Change in Acquisitions & Divestments stood at $174.0 million in 2021, then fell by 6.78% to $162.2 million in 2022, then soared by 79.28% to $290.8 million in 2023, then decreased by 13.76% to $250.8 million in 2024, then grew by 6.74% to $267.7 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $267.7 million (Q4 2025), $225.0 million (Q3 2025), and $298.6 million (Q2 2025) per Business Quant data.